Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

被引：11

作者：

Rubinstein, Jeremy D. ^{[1
,2
]}

Nelson, Adam S. ^{[1
,3
]}

Krupski, Christa ^{[1
,3
]}

O'Brien, William ^{[4
,5
]}

Taylor, J. Michael ^{[1
,6
]}

Badgett, Tom C. ^{[7
]}

Huang, Michael ^{[8
]}

Davies, Stella M. ^{[1
,3
]}

Phillips, Christine L. ^{[1
,2
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA

[2] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, 3333 Burnet Ave,MLC 7015, Cincinnati, OH 45229 USA

[3] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA

[4] Univ Cincinnati, Coll Med, Dept Radiol, Cincinnati, OH USA

[5] Cincinnati Childrens Hosp Med Ctr, Dept Radiol & Med Imaging, Cincinnati, OH 45229 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA

[7] Univ Kentucky, Dept Pediat, Coll Med, Lexington, KY USA

[8] Univ Louisville, Sch Med, Pediat Canc & Blood Disorders, Louisville, KY 40292 USA

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 04期

关键词：

CAR-T; cellular therapy; neurotoxicity; pre-B ALL; CYTOKINE RELEASE SYNDROME; NEUROTOXICITY; BIOMARKERS; CHILDREN;

D O I：

10.1002/pbc.28199

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

引用

页数：5

共 50 条

[1] Chimeric antigen receptor T-cell therapy
Burge, Cale
Vanguru, Vinay
Ho, Phoebe Joy
AUSTRALIAN PRESCRIBER, 2023, 46 (02) : 36 - 39
[2] Chimeric Antigen Receptor T-Cell Therapy
Ogba, Ndiya
Arwood, Nicole M.
Bartlett, Nancy L.
Bloom, Mara
Brown, Patrick
Brown, Christine
Budde, Elizabeth Lihua
Carlson, Robert
Farnia, Stephanie
Fry, Terry J.
Garber, Morgan
Gardner, Rebecca A.
Gurschick, Lauren
Kropf, Patricia
Reitan, Jeff J.
Sauter, Craig
Shah, Bijal
Shpall, Elizabeth J.
Rosen, Steven T.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (09): : 1093 - 1106
[3] Chimeric Antigen Receptor T-Cell Therapy
Rasheed, Azgar Abdul
Koyyala, Venkata Pradeep Babu
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (01) : 89 - 92
[4] Chimeric antigen receptor T-cell therapy for melanoma
Razavi, Azadehsadat
Keshavarz-Fathi, Mahsa
Pawelek, John
Rezaei, Nima
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (03) : 209 - 223
[5] Chimeric antigen receptor T-cell therapy for ALL
Maude, Shannon L.
Shpall, Elizabeth J.
Grupp, Stephan A.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 559 - 564
[6] Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
Reinhardt, Bryanna
Lee, Patrick
Sasine, Joshua P. P.
CELLS, 2023, 12 (04)
[7] Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
Ma, Kun
Hu, Ping
CANCERS, 2023, 15 (23)
[8] Chimeric antigen receptor T-cell therapy toxicities
Greenbaum, Uri
Kebriaei, Partow
Srour, Samer A.
Olson, Amanda
Bashir, Qaiser
Neelapu, Sattva S.
Rezvani, Katayoun
Shpall, Elizabeth J.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2414 - 2424
[9] Chimeric antigen receptor T-cell therapy for glioblastoma
Rodriguez, Analiz
Brown, Christine
Badie, Behnam
TRANSLATIONAL RESEARCH, 2017, 187 : 93 - 102
[10] Biomarkers in chimeric antigen receptor T-cell therapy
Kong, Weimin
Lacey, Simon F.
Melenhorst, Jan Joseph
Fraietta, Joseph A.
BIOMARKERS IN MEDICINE, 2018, 12 (05) : 415 - 418

← 1 2 3 4 5 →